Exercise to Prevent AnthraCycline-based Cardio-Toxicity Study 2.0 (EXACT2)

NAActive, not recruitingINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

April 29, 2019

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Cancer, BreastCardiotoxicityCardiovascular Diseases
Interventions
BEHAVIORAL

Aerobic exercise

All participants will receive standard of care for their cancer as well as given a 12-week, home-based progressive aerobic exercise (AE) program. A nonlinear progressive training approach will be used whereby each participant will perform two AE sessions (e.g. walking), on non-consecutive days, per week. AE sessions will vary between low (35-45% heart rate reserve (HRR)), low-moderate (46-55% HRR), high-moderate (56-70% HRR) and high (71-85% HRR) intensity.

Trial Locations (2)

R2H 2A6

St. Boniface Hospital, Winnipeg

B3H 1V8

QEII Health Sciences Centre, Halifax

All Listed Sponsors
collaborator

Canadian Cancer Society (CCS)

OTHER

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

Nova Scotia Health Authority

OTHER